Baxter/Angiotech CoSeal
This article was originally published in The Gray Sheet
Executive Summary
Surgical sealant and Adhibit surgical anti-adhesive product will be marketed by Baxter under a worldwide (excluding Japan) strategic alliance announced Feb. 25. Angiotech expects an upfront fee of $8 mil., further payments of up to $14.7 mil., and a percentage of sales "in the low double digits." The Canadian firm completed its roughly $42 mil. acquisition of product developer Cohesion Technologies in February (1"The Gray Sheet" Feb. 24, 2003, In Brief)...